Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
  • C12N15/1034—Isolating an individual clone by screening libraries
  • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/64—Cyclic peptides containing only normal peptide links
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Definitions

• the present invention relates to the non-toxic production of cyclic peptides via modifications to a split-intein circular ligation of peptides and proteins (SICLOPPS) methodology for enhanced efficiency within mammalian cells.
• SICLOPPS split-intein circular ligation of peptides and proteins
• cyclic peptides in the early stages of drug discovery has become increasingly prevalent within pharmaceutical research and development. These polypeptides, ranging in length from just two conjoined amino acids to peptides comprising hundreds of such residues, are particularly useful for identifying protein- protein interaction inhibitors, with a further use in serving as key starting points for the design of drug-like small molecules.
• Peptides have a particular utility as ligands against otherwise “undruggable” targets.
• Such undruggable targets may be intracellular molecules, specific protein-protein interactions, and are generally unsuitable to small molecules and biologies.
• the further cydisation, or ring dosure, of peptides enhances the lifespan of such molecules in vivo with a subsequent marked improvement in their pharmacokinetic dynamics. Whilst the scope of useful cydic peptides found in nature is somewhat limited, the production of synthetic polypeptides as such in the laboratory opens an avenue of potential for discovering candidate drugs.
• Inteins are unique autoprocessing protein domains that can undergo a self- excising event from a larger precursor polypeptide through the cleavage of two peptide bonds, whilst ligating the N- and C-termini of the flanking extein sequences with a new peptide bond.
• a “split-intein”, more spedfically, has its polypeptide sequence originating from two genes and can result in the flanking of an extein by two separate N-intein and C-intein domains. Following translation, the two domains non- covalently reassemble into a canonical active intein to carry out protein splidng.
• a SICLOPPS construct encodes a C-terminus intein domain followed by the extein polypeptide sequence to be cydised, and an N-terminus intein domain.
• the flanking regions assodate to give an adive intein that self-exdses and cydises the remaining polypeptide sequence between the C- and N- terminus intein domains as a result of splidng.
• Peptides of varying length and amino add composition can be incorporated into the SICLOPPS method, providing that the first amino add of the target peptide is a nudeophilic cysteine, serine or threonine.
• the technique provides a simple method for generating cydic peptide libraries, requiring just a SICLOPPS plasmid, a degenerate oligonudeotide, and a handful of straightforward molecular biology steps.
• the degenerate oligonudeotide will have been designed to determine the ring size of the cydic peptides, the number of randomised amino acids, and any set amino acids to be incorporated.
• Each oligonudeotide, containing a unique extein sequence of interest is integrated into a SICLOPPS plasmid via PCR-digest and ligation techniques to create a library.
• the plasmid library can then be transformed into cells containing a phenotypic assay, for example, and then screened.
• the identity of the adive cydic peptides is revealed by isolating the SICLOPPS plasmids from cells that show the desired phenotype, followed by DNA sequendng (Tavassoli 2017, Curr Opin Chem Biol 38: 30-35).
• the advent of SICLOPPS introduced the benefit of interfacing cyclic peptide libraries with assays in a variety of organisms: ranging from £ coli, yeast, and mammalian cells. Intracellular functional assays can be conducted against a variety of targets, thus not only assessing affinity of each member of the library, but also its function against the given target.
• SICLOPPS libraries are DNA- encoded, which gives a large amount of control over the makeup of the library and allows a variety of libraries to be easily produced and screened against such targets.
• Examples of variations in SICLOPPS libraries that are easy to implement include: cyclic peptides of different ring sizes, libraries with different amino acid composition, or inclusion of a given amino acid, or motif in a set position in every member of the library.
• the user has absolute control over the makeup of their cydic peptide library via the degenerate oligonudeotide that encodes it.
• Ssp inteins have a relatively slow splice rate and a significant sensitivity to amino acid changes near the splice junctions, meaning that a significant portion of the cyclic peptide library may not actually be cyclic peptides, but rather exist as the partially spliced intein.
• Npu promiscuous inteins engineered from Nostoc punctiforme.
• inteins in mammalian cells were not investigated by Kinsella et al.
• the inventors have surprisingly found that mammalian cells are also susceptible to toxicity arising from active inteins. Prior to this, the problem of intein associated toxicity in mammalian cells was not recognised.
• the inventors have devised a degradation tag system suitable for use in mammalian cells and which obviates the intein-associated toxicity allowing the split intein system to be widely used in mammalian cells for the production of cyclic peptides.
• This invention is based on the surprising discovery that it is possible to alter a mammalian cell-based SICLOPPS methodology to indude intein-attached degradation tags in order to minimise any resultant intein-induced cytotoxidty.
• the attachment of a degradation tag to either the N-terminus or C-terminus intein domain will allow the canonical active intein, following splidng and cydisation of the extein of interest, to be directed for degradation via the mammalian cell's degradation pathway.
• the approach therefore prevents a detrimental accumulation of cytotoxic inteins from being formed during cydic peptide production within mammalian cells.
• Such degradation-tagged inteins can therefore be used in a modified SICLOPPS methodology to produce a cydic peptide library within mammalian cells with greater effidency.
• the intein is able to splice before it is degraded.
• a method for the non- toxic production of a cyclic peptide in a mammalian cell comprising: a) introducing a vector into a mammalian cell, wherein the vector comprises a construct encoding a C-terminus intein domain, a polypeptide sequence to be cyclised, an N-terminus intein domain, and a degradation tag, wherein the degradation tag is attached to at least one intein domain; and b) expressing the construct to produce an intermediate comprising an active intein and the polypeptide sequence, wherein the active intein, once formed, undergoes splicing and cydises the polypeptide and wherein the degradation tag degrades the active intein.
• the invention also provides a mammalian cell produced by the method of the first aspect of the invention.
• the invention provides a cell expressing a cydic peptide wherein the mammalian cell is produced by a method comprising: a) introdudng a vector into the mammalian cell, wherein the vector comprises a construct encoding a C-terminus intein domain and a N-terminus intein domain of a split intein; a polypeptide sequence to be cydised; and a degradation tag, wherein the degradation tag is attached to at least one intein domain; b) expressing the construct to produce an intermediate comprising an active intein and the polypeptide sequence, whereby the adive intein undergoes splicing and cydises the polypeptide and wherein the degradation tag degrades the active intein.
• the invention also provides a library of mammalian cells produced according to the first aspect of the invention, i.e. the library comprises a number of mammalian cells each comprising a different nudeic add that encodes a different cydic peptide, where the nudeic add is a nudeic add of the invention as described herein.
• the library of mammalian cells produced by the method according to the first aspect of the invention comprises at least 128,000 at the cydic peptide level, optionally for example at least 150,000 or at least 200,000 members at the cydic peptide level.
• the library of mammalian cells produced by the method according to the fist aspect of the invention comprises at least 128,000 members, for example at least 130,000, 150,000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1 million, 1.5 million, 2 million, 2.5 million, 3 million, 3.2 million, 3.5 million or at least 4 million members at the protein level.
• the protein level we indude the meaning of the level of the expressed cydized peptide level.
• the cells of the present invention due to the use of the degradation tag comprise no active inteins, or substantially no active inteins, for example no or substantially no toxic active inteins.
• the invention also provides a cell lysate prepared from a mammalian cell of the invention.
• a cyclic peptide library produced by the method according to the first aspect of the invention.
• a genetic construct comprising a polynucleotide cassette encoding a C-terminus intein domain, a polypeptide sequence to be cyclised, an N-terminus intein domain, and a degradation tag suitable for use in mammalian cells, wherein the degradation tag is attached to at least on intein domain and wherein, once expressed, an active intein is formed.
• a vector comprising the genetic construct according to the third aspect of the invention.
• a mammalian cell comprising the vector according to the fourth aspect of the invention or the genetic construct according to the third aspect of the invention.
• the invention also provides a library of mammalian cells comprising the vector according to the fourth aspect of the invention or the genetic construct according to the third aspect of the invention.
• the library of mammalian cells comprises at least 200,000 members, for example at least 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1 million, 1.5 million,
• a sixth aspect of the invention there is provided a method of producing a cyclic library according to the method of the first aspect of the invention.
• Figure 1 shows the initiation of the mechanism of SICLOPPS, in which the N- terminus and C-terminus intein domains, flanking an extein peptide sequence of interest, non- covalently associate to form a canonical active intein (adapted from Townend & Tavassoli 2016, ACS Chem Biol 11(6): 1624-1630).
• Figure 2 shows the mechanism of SICLOPPS following the formation of an active intein. In a three step process involving a thioester intermediate and a lariat intermediate, the active intein splices to cyclise the target peptide extein.
• Figure 3 shows how a cyclic peptide library can be generated from a SICLOPPS plasmid library. Plasmids containing appropriate origins of replication, selectable markers and promoters, and a SICLOPPS construct of interest, are transfected into mammalian cells. Following transcription and translation, the expressed inteins, in this case DnaE inteins, cyclise each peptide of interest to produce an intracellular library of such molecules.
• inteins in this case DnaE inteins
• Figure 4 shows a SICLOPPS construct for an eGFP/YFP peptide designed with the addition of a degradation tag to the N-intein.
• the degradation tag attached is the oxygen dependent degradation (ODD) domain of the hypoxia-inducible factor-1 alpha (HIF-1 ⁇ ) subunit.
• ODD oxygen dependent degradation
• Further additions to the construct include affinity tags, a fluorescent tag of mCherry, and a FLAG tag for antibody recognition.
• Figure 5 shows a fluorescent microscopy image of a SICLOPPS plasmid according to figure 4 that had been transfected into HeLa cells which were subsequently placed in the presence of oxygen with or without 100 ⁇ of deferoxamine (DFX) treatment.
• the inteins should degrade only in the presence of oxygen and absence of DFX.
• the results show that the inteins, associated with mCherry fluorescence, degraded in normoxia in comparison to DFX experiments which displayed mCherry fluorescence.
• Figure 6 shows the fluorescent microscopy image of a SICLOPPS plasmid according to figure 4, further containing a P564G mutation in the degradation tag, that had been transfected into HeLa cells which were subsequently placed in the presence of oxygen with or without 100 ⁇ of deferoxamine (DFX) treatment.
• DFX deferoxamine
• FIG 7 shows a western blot analysis for the wildtype (WT) and P564G mutant SICLOPPS plasmids as described above, which had been transfected into HeLa cells and incubated under normoxia, hypoxia, or DFX-treated conditions.
• the hypoxia and DFX conditions showed no intein degradation for the wildtype plasmid, whilst the inteins were degraded in normal oxygen conditions.
• Figure 8 shows the cell counts over 48 hours for HeLa cells transfected with the WT and P564G mutant SICLOPPS plasmids as described above, under normoxia or hypoxia.
• Figure 9 shows Trex293 cells transfected with plasmids encoding GFP-Npu-ODDD- mCherry.
• Splicing WT
• C1A non-splicing
• Gates represent Q1: mCherry+ GFP-, Q2: mCherry+ GFP+, Q3: mChenry- GFP+, Q4: mCherry- GFP-.
• SEQ ID NO: 1 is an amino acid sequence for the C-terminus intein domain of an Ssp DnaE split intein, isolated from Synechocytis sp. strain PCC6803.
• SEQ ID NO: 2 is an amino acid sequence for the corresponding N-terminus intein domain of an Ssp DnaE split intein, isolated from Synechocytis sp. strain PCC6803.
• SEQ ID NO: 3 is an amino acid sequence for the C-terminus intein domain of an Npu DnaE split intein, isolated from Nostoc sp. strain PCC73102.
• SEQ ID NO: 4 is an amino acid sequence for the corresponding N-terminus intein domain of an Npu DnaE split intein, isolated from Nostoc sp. Strain PCC73102.
• SEQ ID NO: 5 is an amino acid sequence for the C-terminus intein domain of an artificial Cfa DnaE split intein engineered for enhanced stability and activity.
• SEQ ID NO: 6 is an amino acid sequence for the corresponding N-terminus intein domain of an artificial Cfa DnaE split intein engineered for enhanced stability and activity.
• SEQ ID NO: 7 is an amino acid sequence for the C-terminus intein domain of an “ultrafast” gp41-1 DnaE split intein engineered for very fast splicing activity.
• SEQ ID NO: 8 is an amino acid sequence for the corresponding N-terminus intein domain of an “ultrafast” gp41-1 DnaE split intein engineered for very fast splicing activity.
• SEQ ID NO: 9 is an amino acid sequence for Homo sapiens hypoxia-inducible factor- 1 alpha (HIF-1 ⁇ ) subunit comprising the oxygen dependent degradation (ODD) domain, which may be used as a degradation tag.
• SEQ ID NO: 10 is an amino acid sequence for the oxygen dependent degradation (ODD) domain of Homo sapiens hypoxia-inducible factor-1 alpha (HIF-1 ⁇ ) subunit, which may be used as a degradation tag.
• the invention is predicated on the surprising discovery that the addition of a degradation tag to a SICLOPPS-based methodology allows for the production of cyclic peptides within mammalian cells without generating an accumulation of cytotoxic intein by-products. Cyclic peptides can thus be produced in mammalian cells without the low efficiency levels normally associated with such a method.
• cydic peptide refers to a polypeptide or protein that has been “cydised”, in which its constituent atoms form a ring.
• a linear peptide is cydised when its free amino (N)-terminus is covalently bonded to its free carboxy (C)-terminus, i.e. in a head to tail format, such that no free C- or N-termini remain in the peptide.
• the terms “peptide” and “polypeptide” can be used interchangeably.
• the invention provides a method of producing cyclic peptides within mammalian cells by an altered SICLOPPS methodology to incorporate the use of degradation tags.
• mammalian cell refers to a eukaryotic cell with structurally defined intracellular organisation, as opposed to bacteria and archaea. Mammalian cells are often used in cell culture, for example the use of Chinese Hamster Ovary (CHO) cells, the most common mammalian cell line used for mass production of therapeutic proteins (Wurm 2004, Nat Biotech 22(11): 1393-1398).
• CHO Chinese Hamster Ovary
• SICLOPPS or the “split-intein circular ligation of peptides and proteins” takes advantage of intein splicing for the generation of a cyclic peptide.
• intein means a naturally-occurring or artificially constructed polypeptide sequence embedded within a precursor protein that can catalyse a splidng reaction during post-translation processing of the protein.
• An intein can excise itself from the precursor protein and join the remaining portions with a peptide bond in a process named “splidng”.
• a “split-intein” is an intein that has two or more separate components not fused to one another, encoded by two separate genes. In some cases, the split-intein components will flank a polypeptide sequence therein referred to as an “extein”. When flanking an extein, the split-intein components are referred to as an N-terminus and C- terminus intein domain in respect to the N- and C-termini of the extein.
• the intein is an intein that is toxic to mammalian cells.
• toxic we include the meaning that the intein negatively affects the growth rate of the mammalian cells, or causes apoptosis or necrosis.
• the mammalian cells can be any mammalian cells in which it is desirous to express a cydic peptide.
• inteins More than 350 types of inteins are recognised at present, each or which can have differing rates of catalysing a splicing reaction.
• the nomenclature of inteins is based on the scientific name of the organism to which it is found. Ssp inteins, for example, were first isolated from Synechocytis spp, whilst faster splicing Npu inteins were first isolated from Nostoc punctiforme.
• a database comprising a list of some of the known inteins can be found at http://www.biocenter.helsinki.fi/bi/iwai/lnBase/tools.neb.com/inbase/list.html.
• the intein used in the invention may be any intein that would splice faster than its degradation time by an attached degradation tag.
• the skilled person can select an appropriate intein for use with a corresponding degradation tag.
• the intein may be a Cfa intein.
• the intein may be a split Cfa intein comprising the amino add sequences of SEQ ID NO: 5 and SEQ ID NO: 6 for the C-terminus and N-terminus intein domains, respectively.
• the intein may be an Ssp intein. In a further preferred embodiment the intein may be a split Ssp intein comprising the amino add sequences of SEQ ID NO: 1 and SEQ ID NO: 2 for the C-terminus and N- terminus intein domains, respectively. In another preferred embodiment the intein may be a gp41-1 intein. In a further preferred embodiment the intein may be a split gp41-1 intein comprising the amino add sequences of SEQ ID NO: 7 and SEQ ID NO: 8 for the C-tenminus and N- terminus intein domains, respectively.
• the intein may be an Npu intein.
• the intein may be a split Npu intein comprising the amino add sequences of SEQ ID NO: 3 and SEQ ID NO: 4 for the C-terminus and N- terminus intein domains, respectively.
• a SICLOPPS method makes use of a construct containing a C-terminus intein domain followed by an extein polypeptide sequence to be cydised, and an N-terminus intein domain.
• the construct is arranged as such so that, following translation of the mRNA sequence, the N- and C-terminus intein domains flanking the intervening extein are capable of non-covalently associating to form a functional active intein ( Figure 1) that subsequently catalyses the splidng reaction that produces the cyclic polypeptide.
• the folded SICLOPPS construct, or “fusion protein”, with its active canonical intein will catalyse an N-to-S acyl shift at the N-terminus intein domain and extein junction to produce a thioester intermediate.
• the thioester intermediate will undergo transesterification with a side-chain nucleophile at the opposite C-tenminus intein domain and extein junction to form a lariat intermediate.
• an asparagine side-chain cydisation and subsequent X-N acyl shift liberates the cydic peptide from the intein (Scott et al., 1999, PNAS 96(24): 13638-13643).
• X is the extein and cyclic peptide to be produced; X is C, S, or T, and denotes an amino acid of the cyclic peptide sequence. It is necessary for the functioning of the splicing that the first position may be occupied by an invariant cysteine, serine, or threonine residue. It will be apparent to one skilled in the art that any sequence may be inserted after “X" in the sequence above. The sequence may be one or more amino acids in length.
• sequence may be three or more amino acids in length. In a most preferred embodiment the sequence may be at least six amino acids in length.
• an optional hexahistidine (6xHis) tag to assist in purification, or any other such affinity tag may be induded within the construct.
• the base SICLOPPS construct will further indude an affinity tag.
• the construct will indude a 6xHis tag.
• the construct will indude a 2xStrep tag.
• the SICLOPPS construct may be further modified to include a tag for antibody recognition.
• the tag for antibody recognition may be a FLAG tag.
• the invention provides an altered SICLOPPS method wherein the SICLOPPS construct, as exemplified above, is modified with the addition of a degradation tag, suitable for use in mammalian cells, attached to either of the N-terminus or C-terminus intein domains.
• degradation tag is intended to encompass peptide sequences that mark a protein for degradation by a cell’s degradation machinery.
• a major pathway of selective protein degradation is the ubiquitin- proteasome pathway.
• Ubiquitin-dependent protein degradation has a natural role in many biological processes, including signal transduction, cell cycle progression, and transcriptional regulation (Groulx & Lee 2002, Mol Cell Biol 22(15): 5319-5336).
• Ubiquitin is a small regulatory protein that can be added to a substrate protein in a process called ubiquitination.
• the conjugation of ubiquitin is an ATP-dependent process that involves three enzymes: E1 and E2 proteins prepare the ubiquitin for conjugation; E3 ubiquitin ligases recognise the specific protein substrate to catalyse the transfer activated ubiquitin molecule. Once a protein is tagged with a single ubiquitin molecule, other E3 ubiquitin ligases are signalled to attach further ubiquitin molecules, resulting in a polyubiquitin chain attached to the substrate protein.
• Proteins tagged for ubiquitination are subsequently targeted to a cellular proteasome complex wherein the ubiquitin chain is recognised by the proteasome, and the bound proteins are degraded into peptides of seven to eight amino acids long.
• Degradation tags can thus function by engaging the tagged protein with an E3 ubiquitin ligase resulting in the addition of a polyubiquitin chain and subsequent degradation by the proteasome.
• an altered SICLOPPS method that uses a construct as described above which may comprise a degradation tag attached to either the N-terminus or C-terminus intein domain.
• the attached degradation tag may effect degradation at least in part by ubiquitination.
• the attached degradation tag may be a hypoxia- inducible factor-1 alpha (HIF-1 ⁇ ) subunit.
• the attached degradation tag may comprise the oxygen dependent degradation domain of HIF-10 that engages an ubiquitin ligase complex.
• the attached degradation tag may comprise the amino add sequence according to SEQ ID NO: 10.
• the attached degradation tag may be a tag or proteolysis targeting chimera that engages an E3 ubiquitin ligase for protein degradation.
• Hypoxia-inducible factors are heterodimeric transcription factors comprising a constitutively expressed HIF-1 ⁇ subunit and a HIF-1 ⁇ subunit regulated by oxygen.
• HIF-10 comprises an oxygen dependent degradation (ODD) domain that contains a key proline residue P564 that is hydroxylated in normoxia to target the HIF-1 a subunit for proteasomal degradation by engaging an ubiquitin ligase complex.
• ODD oxygen dependent degradation
• the ubiquitin ligase complex comprises a von Hippel-Lindau tumour suppressor protein (VHL) responsible for recognising the hydroxylated P564 residue of the ODD domain of HIF-
• VHL von Hippel-Lindau tumour suppressor protein
• a P564-comprising sequence from the ODD domain of HIF-1 a as a degradation tag thus induces degradation of the attached protein.
• the active intein upon expression of the SICLOPPS construct, the active intein, following its self-excision and splicing and cyclisation of the extein of interest, is attached from either its N-terminus or C-terminus domain to the P564-comprising polypeptide of the ODD domain.
• the hydroxylated P564 residue is recognised by the VHL from an ubiquitin ligase complex, and ubiquitinated and degraded by the proteasome along with the attached cytotoxic active intein.
• polypeptide construct as described above for use in the altered SICLOPPS methodology may further contain amino acids 548- 603 of the full length ODD domain of HIF-1 ⁇ , containing the key P564 for hydroxylation, attached to the N-terminus intein domain, as comprised by the following sequence: ID NO: 16) Wherein: (SEQ ID NO: 17)
• a proteolysis targeting chimera can similarly function as a degradation tag.
• a PROTAC is a small molecule comprising two covalently linked protein-binding domains. One domain is capable of engaging an E3 ubiquitin ligase, whilst the other binds to a target protein meant for degradation.
• the incorporation of a PROTAC as a degradation tag for either the N-terminus or C-terminus thus results, upon expression of the SICLOPPS construct, in the recruitment of an E3 ubiquitin ligase to the exdsed active intein to result in its ubiquitination and proteasomal degradation.
• cytotoxidty refers to a toxic quality of a compound towards cells which may result in such cells undergoing necrosis, wherein they die rapidly due to cell lysis from a loss of membrane integrity, or apoptosis, wherein the cells undergo programmed cell death. Cytotoxic effects would have an impact on the level of efficiency in utilising mammalian cells for the purposes of producing cyclic peptides, for example, as would be understood by the skilled reader.
• a degradation tag may induce degradation of the protein or polypeptide it is attached to regardless of whether the attachment is direct in sequence or via a linker.
• linkers, or spacers are short amino acid sequences that vary between 2 and 31 amino acids, implemented to separate multiple domains of a single protein.
• the degradation tag is attached via a direct linkage.
• a compatible degradation tag will be incorporated into the SICLOPPS construct relative to the type of inteins used. It would be apparent to the skilled reader that the active intein need splice before it is degraded by the induded degradation tag, or in other words, the degradation tag needs to induce degradation slower than the intein splices.
• fluorescent tags may be attached to the degradation tags within the SICLOPPS construct; hence any degradation of the resultant expressed tagged proteins could be visualised using fluorescence microscopy or other such techniques known within the field.
• fluorescence microscopy or other such techniques known within the field.
• a wide range of fluorescent tags, or fluorophores exist that are suitable for use in microscopy. A comprehensive list of fluorophores is available at https://www. biosyn . com .
• the fluorescent tag is attached to the degradation tag incorporated within the SICLOPPS construct.
• the fluorescent tag is a DsRed fluorophore.
• the modified SICLOPPS construct will be introduced into mammalian cells within any suitable expression vector that can fadlitate expression of the polynudeotide.
• expression vector means a vehicle that facilitates transcription and/or translation of a nucleic acid molecule in a suitable in vitro or in vivo system.
• An expression vector is “indudble” when adding an exogenous substance to a host system containing the expression vector causes the vector to be expressed, for example causing a nudeic add molecule within the vector to be transcribed into mRNA.
• Such suitable vectors indude plasmids (Fig. 4), bacteriophages, and viral vectors. A large number of these are known in the art, and many are commercially available or obtainable from the sdentific community. Those of skill in the art can select suitable vectors for use in a particular application based upon, for example, the type of system selected such as mammalian cells and the expression conditions selected.
• Expression vectors used within the method can indude a stretch of nudeotides that encodes a target polypeptide construct and a stretch of nudeotides that operate as a regulatory domain that modulates or controls expression of nudeotide sequences within the vector.
• the regulatory domain can be a promoter or an enhancer.
• an expression vector of the invention can be an indudble expression vector such as an arabinose indudble vector.
• indudble expression vector such as an arabinose indudble vector.
• Plasmids can be transfected into mammalian cells for transient expression through several well practiced techniques within the art, such as chemical-based or electroporation-based transfection.
• an expression vector used within the present invention will comprise a suitable origin of replication (ORI) for use in mammalian cells. Since there are no “natural” mammalian ORIs, viral-based ORIs are often used for expression vectors intended for mammalian cells, such as viral Epstein-Barr virus (EBC) or SV40 ORIs.
• EBC Epstein-Barr virus
• an altered SICLOPPS method that utilises a plasmid comprising a modified SICLOPPS construct as outlined above suitable for expression within mammalian cells.
• the plasmid comprises a SV40 origin of replication suitable for expression within mammalian cells.
• the present invention provides a cyclic peptide library produced by the altered SICLOPPS method according to the first aspect of the invention.
• cyclic peptide library refers to a multiple of compartmentalised cyclic peptides, often containing over 100 million peptide members.
• Each member of the library may be expressed within a mammalian cell from a unique plasmid as described in the first aspect of the invention. It is envisaged that the library will contain great numbers of randomised cyclic peptides from each expressed plasmid, generated as such so that the polypeptide of interest, or extein, is randomised.
• the randomised polypeptide is essentially a degenerate oligonucleotide, wherein “degenerate” refers to its sequence containing a number of possible nucleotide bases.
• the resultant library would in theory contain a great number of possible cyclic peptide structures that may subsequently be used for pharmaceutical assays and other research purposes.
• the generation of cyclic peptide libraries within cells allows for functional assays to be conducted against a variety of targets.
• SICLOPPS-based libraries are DNA-encoded, which gives a large amount of control over the makeup of the library and allows a variety of libraries to be easily produced and screened against a given target ( Figure 3).
• Such variations in SICLOPPS libraries that are easy to implement include: cyclic peptides of different ring sizes; libraries with different amino acid composition, using limited codon sets; or, inclusion of a given amino acid, or motif in a set position in every member of the library.
• the SICLOPPS user has absolute control over the makeup of their cyclic peptide library via the degenerate oligonucleotide that encodes it.
• the length of the randomised polynucleotide inserted into the vector will be dependent on various factors that may be determined by the skilled person. Of primary consideration is the size of the ultimate polypeptide expressed, and subsequent ring size of the cyclic peptide. In a preferred embodiment, the polypeptide is 6 amino acids in length. A suitable randomised polynudeotide would therefore be 18 nucleic acids in length. For cydic peptide formation, consideration must be given to whether the length of the polypeptide is suffident to allow the cydisation reaction to proceed, i.e. whether the length allows a dosed peptide cyde to form. In some embodiments, the peptide is cydised by a linker of any length.
• cydic polypeptides may be achieved by encoding just two amino acids, in which case the randomised polynudeotide will be at least 6 nudeic acids in length. Another consideration is the maximum insert size tolerated by the vector and corresponding replication system.
• the randomised sequence may be longer, for example, at least 9, 30, 60, 90, 180, 300, 600, 900, 1 ,800, 3,000, or more nudeic acids in length.
• the randomised nudeotide sequence is 6, 9, 12, 15, 18, 21, 24, 27, or 30 nudeotides in length.
• the randomised sequence is intended to encode a polypeptide, its length may not necessarily be a multiple of 3.
• the randomised polynudeotide sequence may also be referred to herein as the variable sequence.
• one or more positions of the "random" or “variable” sequence may actually be fixed.
• the first position may be occupied by an invariant cysteine, serine, or threonine residue, followed by a variable or random amino acid sequence as described within the first aspect of the invention.
• a genetic construct comprising a polynudeotide cassette encoding a C-terminus intein domain, a polypeptide sequence to be cydised, an N-tenminus intein domain, and a degradation tag suitable for use in mammalian cells, wherein the degradation tag is attached to at least on intein domain and wherein, once expressed, an active intein is formed.
• the genetic construct may further contain any of the modifications or spedfications according to the first aspect of the invention.
• a vector comprising the genetic construct according to the third aspect of the invention.
• a mammalian cell comprising the vector according to the fourth aspect of the invention.
• Example 1 A SICLOPPS construct was designed with the addition of a degradation domain to the N-terminus intein domain, resulting in the depletion of the spliced intein product to prevent toxicity in mammalian cells. Cfa inteins were used for fast splicing and high promiscuity, containing an ERD to GEP mutation at residues 122-124 for increased amino acid tolerance at the +2 residue. The construct was designed with the following sequence:
• N-terminus intein domain (SEQ ID NO: 19) The extein, in which eGFP was utilised in this example f+N-tenminus 2xStreo tag). Wildtype Cfa splice junctions (CFN & AEY) were incorporated to improve efficiency:
• ODD oxygen dependent degradation domain from HIF-1 ⁇ , comprising the key residue P564 for hydroxylation, was incorporated C-terminus to N-terminus intein domain: (SEQ ID NO: 21)
• the fluorescent protein mCherry was further fused C-terminal to ODD domain, followed by a FLAG tag for antibody recognition:
• Wildtype or WT - will splice and degrade.
• Example 2 The two plasmids from example 1 were independently transfected into HeLa cells which were subsequently placed in the presence of oxygen without or with 100 ⁇ of DFX treatment, in order to prevent the degradation of the inteins.
• the inteins should only degrade in the presence of oxygen and be stabilised in the absence of oxygen or in the presence of DFX, due to inhibition of the HIF prolyl hydroxylase domain (PHD).
• PHD HIF prolyl hydroxylase domain
• the inteins should never degrade, either in the presence of oxygen or with DFX treatment.
• the proline has been mutated into a glycine, hence preventing the proline from being hydroxylated by PHDs and the subsequent degradation of the protein.
• HeLa cells were imaged using a Zeiss fluorescent microscope to determine whether the extein (GFP) and the inteins (mCherry-tagged) were present depending upon the conditions.
• the wildtype and P564G plasmids from examples 1 and 2 were transfected into HeLa cells which were then incubated for 24 hours in normoxia, hypoxia, or DFX-treated conditions. Cells were then lysed using RIPA buffer and scrapers. Total protein lysates were analysed by western blot, the results of which are shown in Figure 7. Strep tags were used to capture GFP, whilst FLAG tags were used for mChenry. Anti-FLAG and anti-Strep tag antibodies were recognized using secondary antibodies coupled to Alexa 488 and Alexa 568, respectively.
• the trend shows maintenance of live cell numbers in wildtype- transfected cells, versus a decrease in live cell number in P564G in normoxia.
• Cells incubated with hypoxia might show a decrease in cell number, i.e. toxicity, from 48h for both plasmids, wherein degradation of the inteins is not occurring.
• Trex293 cells were plated into 6 cm dishes. Next day, cells were transfected with 1 ug of plasmid and one well remained non-transfected to use as negative control to set fluorescence gates. Next day, media was changed, 1ug/mL of doxycycline was added to each dish and in the dishes of treated cells, DFX was added to a final concentration of 100 ⁇ . Cells were analysed by FACS on the following day. Results: We investigated whether the inteins fused to mCherry and the Oxygen- Dependent-Degradation-Domain (ODDD) were degrading in presence of oxygen and if addition of DFX could prevent this oxygen-dependent degradation.
• ODDD Oxygen- Dependent-Degradation-Domain
• Trex cells integrated with CFA inteins - peptide extein - ODDD - mCherry (splicing and ncn-splicing) were plated at a density cf 1000 cells per well in 96-well plates. Next day, media was changed and replaced with fresh media containing doxy cycline (1 ⁇ g/mL) with or without DFX (100 ⁇ final concentration). Next day, cell viability was measured using Cell Titer Glo Assay.
• This viability assay confirms that upon treatment with dfx, shown to result in a decrease in the degradation of the inteins, cell viability significantly decreases ( Figure 11). This suggests that the presence of the inteins in the cell has a negative effect upon cell viability.
• the -dfx control results in the degradation of the inteins and subsequently increased viability.
• the C1A non-splicing control confirms that this is not a result on extein toxicity, as no spliced extein is present.
• SEQ ID NO: 1 Amino acid sequence for Ssp DnaE C-terminus intein domain
• SEQ ID NO: 2 Amino acid sequence for Ssp DnaE N-terminus intein domain
• SEQ ID NO: 3 (Amino acid sequence for Npu DnaE C-terminus intein domain)
• SEQ ID NO: 4 Amino acid sequence for Npu DnaE N-terminus intein domain
• SEQ ID NO: 5 (Amino acid sequence for Cfa DnaE C-terminus intein domain) VKIISRKSLGTQNVYDIGVEKDHNFLLKNGLVASN
• SEQ ID NO: 6 Amino acid sequence for Cfa DnaE N-terminus intein domain
• SEQ ID NO: 7 (Amino acid sequence for gp41-1 C-terminus intein domain)
• SEQ ID NO: 8 (Amino acid sequence for gp41-1 N-terminus intein domain)
• SEQ ID NO: 9 Amino acid sequence for Homo sapiens hypoxia-inducible factor-1 alpha [HIF-1 ⁇ ] subunit
• SEQ ID NO: 10 Amino acid sequence for the oxygen dependent degradation (ODD) domain of Homo sapiens hypoxia-inducible factor-1 alpha [HIF-1o] subunit

Landscapes

• Genetics & Genomics (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Zoology (AREA)
• Biomedical Technology (AREA)
• Wood Science & Technology (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Microbiology (AREA)
• Physics & Mathematics (AREA)
• Plant Pathology (AREA)
• Crystallography & Structural Chemistry (AREA)
• Bioinformatics & Computational Biology (AREA)
• Medicinal Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=69186767

Family Applications (1)

Country Status (7)

Cited By (2)

Citations (1)

Family Cites Families (2)

• 2019
  • 2019-12-18 GB GBGB1918693.1A patent/GB201918693D0/en not_active Ceased
• 2020
  • 2020-12-17 JP JP2022537314A patent/JP7665628B2/ja active Active
  • 2020-12-17 CA CA3164788A patent/CA3164788A1/en active Pending
  • 2020-12-17 CN CN202080088650.XA patent/CN114867854A/zh active Pending
  • 2020-12-17 EP EP20838195.4A patent/EP4077662A1/en active Pending
  • 2020-12-17 US US17/787,061 patent/US20240279646A1/en active Pending
  • 2020-12-17 WO PCT/GB2020/053263 patent/WO2021123789A1/en not_active Ceased

Patent Citations (1)

Non-Patent Citations (12)

Also Published As

Similar Documents

Legal Events